Healthy Clinical Trial
Official title:
Effects of Non-invasive Stimulation on Central Nervous System Excitability of Healthy Volunteers
A crossover trial with healthy volunteers will be conducted. Six sessions will be performed once a week in a counterbalanced order and at least with seven days washout period to minimize carry-over effects. In each session, volunteers will be submitted to quantity and quality of sleep, type of eating, fatigue and motivation level, cortical brain activity measures through paired pulse transcranial magnetic stimulation (ppTMS), spinal cord activity measures through electrical stimulation, non-invasive spinal stimulation (tsDCS) or non-invasive brain stimulation (rTMS) and physical exercise (gait training).
After given prior informed consent, volunteers will be submitted to six pseudorandomized
sessions using a website (randomization.com) by a non-involved researcher. At study
beginning, volunteers will be evaluated through structured questionnaire and each session,
will comprise the following experimental sequence:
1. Quantity and quality of sleep: It will be enquired how many hours the volunteer slept in
the last night. The quality of the sleep will be measured through an analogue scale
graded from 0 (worst quality of sleep) to 10 points (best quality of sleep).
2. Type of eating: All the individuals will be asked about ingestion of food and drinks
that could change the cortical excitability ( e. g.; coffee, chocolate, energetic, soda
e etcc). If positive, researchers will record the time since of ingestion and quantify
the amount of food.
3. Fatigue and motivation level: Fatigue and motivation level: Fatigue and motivation
levels: It will be measured through an analogue scale graded from 0 (lower fatigue or
motivation levels) to 10 points (greater fatigue or motivation levels).
4. Cortical excitability: the cortical will be measured through the motor evoked potential
(MEP), short intracortical inhibition (SICI) and intracortical facilitation (ICF). All
the measures will be evaluated through transcranial magnetic stimulation (Neurosoft,
Russia). Initially, rest motor threshold (RMT) will be determined by finding the lowest
stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV).
For RMT measure, a figure-eight coil connected to the magnetic stimulator held manually
at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 -
10/20 System). The short intracortical inhibition (SICI) and intracortical facilitation
(ICF) will be evaluated by paired pulse transcranial magnetic stimulation. A
subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (130% of
RMT) will be delivered at an interstimulus interval (ISI) of 2 milliseconds for SICI and
10 milliseconds for ICF. Ten stimuli will be applied at each condition (unconditioned
pulse and pairs of stimuli with ISI of 3 and 20 milliseconds). Stimuli order delivery
will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus
percentage regarding unconditioned stimulus. The MEP value will be obtained through
single pulse transcranial magnetic stimulation. Ten suprathreshold (130% of RMT) stimuli
will be delivered on primary motor cortex (C3).
5. Spinal cord activity: the level of excitability of spinal cord will be measured through
the following outcomes:
- Hoffman reflex (H reflex): the H reflex will be elicited by a percutaneous
electrical stimulation on tibial nerve delivered on popliteal fossae and recorded
the electromyographic responses from the soleus muscle. The values of maximal H
reflex, M wave and maximal H reflex and maximal M wave ratio (H/M ratio) will be
obtained through a recruitment curve. The recruitment curve will start with a
stimulus intensity delivered from 2 milliampere (mA) and increasing on steps of 1
mA until to M wave curve stabilization (no increasing of the M wave amplitude).
- Homosynaptic depression (HD): the HD will be obtained through a serie of two
consecutive stimuli separated by a interstimulus interval (from 30ms until
10.000ms). The stimuli will be delivered on popliteal fossa and the
electromyographic responses from soleus muscle will be recorded. The stimuli will
be delivered with the intensity necessary to produce the maximal H reflex (this
information will be available in the recruitment curve as stated before). The
difference between the first and the second stimuli for each interstimulus interval
will give rise to the recovery curve.
- Nociceptive component of Withdrawal reflex (RIIIr): The RIIIr wil be elicited by
delivering percutaneous electrical stimulation on sural nerve (behind the right
lateral malleolus) and recording responses from the ipsilateral brevis head of the
biceps femoris muscle. For the reflex threshold (RT) record, the initial current
intensity will be adjusted to 2 mA and increased on steps of 1 mA, until obtain a
response of at least 20 µV, accompanied by pain report. Then, 5 stimulus (130% RT)
will be applied to obtain the latency and area average. Besides, pain perception
will be controlled through an analogue scale graded from 0 (without perception of
pain) to 10 points (greater pain already felt).
6. tsDCS: transcutaneous spinal cord stimulation will be delivered through a direct current
(DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge
electrodes (35cm²). The active electrode (anode or cathode) will be placed between the
eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right
arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade
out of 10 seconds, during 20 minutes. Sham tsDCS has been used in several studies to
evaluate active tsDCS effects. Sham tsDCS will be applied using the same electrodes
placement and parameter settings of anodal tsDCS however, stimulation will last only 30
seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus,
early sensations (eg. mild to moderate tingling or itch) on stimulation site will be
experienced without inducing any modulatory effects. Moreover, after each tsDCS session,
an adverse effects questionnaire will be applied.
7. rTMS: Initially, the higher cortical representation area (hotspot) of first right dorsal
interosseous (FDI) muscle will be determined through a figure-eight coil connected to
the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the
scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the
target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on
previous studies. Low frequency protocol: 1 hertz (Hz), 90% RMT, 1500 stimuli (1 train).
High frequency protocol: 20 Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval
of 28 seconds, 1800 stimuli. Sham rTMS will be performed with low frequency protocol
using two coils. The first one - connected to the stimulator - will be positioned on a
coil support close to the volunteer but not visible. Therefore, characteristic
stimulation noises will be audible. The second - disconnected to the stimulator - will
be placed over left primary motor area. After each rTMS session, presence of adverse
effects will be computed.
8. Gait training: It consists of moderate gait training exercise for 20 minutes. To ensure
that the exercise will be performed at moderate intensity will be used the 64% - 76% of
maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes
through a heart polar. In addition will be monitored perceived effort, gait speed and
incline of the treadmill. The Borg scale will be used to evaluate perceived effort. This
is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise).
Information about the exercise on the treadmill will be noted in the evolution record.
9. Spinal cord activity: this evaluation will be performed immediately after (T0), thirty
minutes after (T1) and 1 hour after (T2) the gait training. The procedures will be
conducted following the same protocol.
10. Cortical brain activity: this evaluation will be performed after each revaluation of
spinal cord activity (T0, T1 and T2). The procedures will be conducted following the
same protocol.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |